Skip to main content
. 2021 Jul 23;19:78–84. doi: 10.1016/j.phro.2021.06.001

Table 1.

Mean dose reductions in percentage for heart and left ventricle at each CRDG gating phase compared to RSG plans.

OAR Target/phase Left Atrium Left ventricular free wall Right atrium Right atrium free wall Right ventricle Interventricular septum Mitral valve Average ± SD
Heart Diastole 35% 32% 35% 16% 14% 24% 41% 28 ± 10%
Systole 12% 5% 19% 18% 39% 37% 18% 21 ± 12%



Left ventricle Diastole 44% 31% 29% 0% 15% 36% 57% 30 ± 17%
Systole 14% 4% 3% 0% 26% 11% 0% 8 ± 9%